Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515 Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

Secretary of the Senate Received: Feb 14, 2008

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name:
PODESTA GROUP, INC
2. Address: 1001 G STREET, NW SUITE 900 EAST, WASHINGTON, DC 20001
Principal place of business (if different from line 2):
4. Contact Name: KIMBERLEY FRITTS Telephone: 2023931010 E-mail (optional): LOBBYING@PODESTA.COM
Senate ID #: 31680-238 House ID #:
7. Client Name: Self
GENZYME
TYPE OF REPORT
8. Year 2007 Midyear (January 1 - June 30): OR Year End (July 1 - December 31): 🔀
9. Check if this filing amends a previously filed version of this report:
10. Check if this is a Termination Report: => Termination Date: 11. No Lobbying Activity:
INCOME OR EXPENSES
Complete Either Line 12 OR Line 13
12. Lobbying Firms
INCOME relating to lobbying activities for this reporting period was:
Less than \$10,000:
\$10,000 or more: X => Income (nearest \$20,000): 80,000.00
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to th registrant by any other entity for lobbying activities on behalf of the client).
13. Organizations
EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000:
\$10,000 or more: => Expenses (nearest \$20,000);
14. Reporting Method. Check box to indicate expense accounting method. See instructions for description of options.
Method A. Reporting amounts using LDA definitions only Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Page 1

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed

- 15. General issue area code: BUD (one per page)
- 16. Specific lobbying issues:
- S. 1710, Labor-HHS-Education and Related Agencies Appropriations Act, Medicare, healthcare provisions H. R. 2764, Foreign Operations and Related Programs Appropriations Act, 2008, (Division A, Division G) H. R. 3043, Labor-HHS-Education and Related Agencies Appropriations Act, Medicare, healthcare provisions
- 17. House(s) of Congress and Federal agencies contacted: Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) HOUSE OF REPRESENTATIVES Health & Human Services, Dept of (HHS) SENATE
- 18. Name of each individual who acted as a lobbyist in this issue area:

Name: COHEN, SHARON
Covered Official Position (if applicable): N/A
Name: KAUDERS, ANDREW
Covered Official Position (if applicable): SR. ADV. SEN. MENENDEZ; ED, HOUSE DEM CAUCUS
Name: MORRA, ELIZABETH
Covered Official Position (if applicable): N/A
Name: PODESTA, ANTHONY
Covered Official Position (if applicable): N/A
Name: POLAK, ANN MARIE
Covered Official Position (if applicable): LEG. CORRESPONDENT FOR REP. MIKE FERGUSON

19. Interest of each foreign entity in the specific issues listed on line 16 above. None

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as

- 15. General issue area code: CPT (one per page)
- 16. Specific lobbying issues:
- S. 1145, Patent Reform Act of 2007 H R. 1908, Patent Reform Act of 2007
- 17. House(s) of Congress and Federal agencies contacted: HOUSE OF REPRESENTATIVES SENATE
- 18. Name of each individual who acted as a lobbyist in this issue area:

Name: COHEN, SHARON Covered Official Position (if applicable): N/A Name: HAGEN, COURTNEY Covered Official Position (if applicable): N/A Name: PODESTA, ANTHONY

Covered Official Position (if applicable): N/A

Name: POLAK, ANN MARIÈ

Covered Official Position (if applicable): LEG. CORRESPONDENT FOR REP. MIKE FERGUSON

19. Interest of each foreign entity in the specific issues listed on line 16 above. None

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed

- 15. General issue area code: MMM (one per page)
- 16. Specific lobbying issues:
- H. R. 4, Medicare Prescription Drug Price Negotiation Act, Medicare "non-interference" provisions H. R. 976, Small Business Tax Relief Act of 2007 S. 1376, 340B Program Improvement and Integrity Act of 2007, 340 B drug price expansion S. 1893, Children's Health Insurance Program Reauthorization Act of 2007 S. 2499, Medicare, Medicaid, and SCHIP Extension Act of 2007 S. 3, Medicare Prescription Drug Price Negotiation Act, Medicare "non-interference" provisions SCHIP (Senate), Medicare cuts to finance SCHIP expansion H. R. 2606, 340B Program Improvement and Integrity Act of 2007, 340 B drug price expansion H. R. 3162, Children's Health and Medicare Protection Act of 2007
- 17. House(s) of Congress and Federal agencies contacted: HOUSE OF REPRESENTATIVES SENATE
- 18. Name of each individual who acted as a lobbyist in this issue area:

Name: BRATHWAITE, PAUL
Covered Official Position (if applicable): EXEC. DIR., CONGRESSIONAL BLACK CAUCUS
Name: COHEN, SHARON
Covered Official Position (if applicable): N/A
Name: GERARD, RANDALL
Covered Official Position (if applicable): N/A
Name: HUNTLEY, AMANDA
Covered Official Position (if applicable): N/A
Name: PODESTA, ANTHONY
Covered Official Position (if applicable): N/A
Name: POLAK, ANN MARIE

anie, Pobar, Arm Marie Covered Official Position (if applicable): LEG. CORRESPONDENT FOR REP. MIKE FERGUSON

Name: SLENZAK, LANTIE

Covered Official Position (if applicable): LEGISLATIVE DIRECTOR, REP. GENE GREEN

19. Interest of each foreign entity in the specific issues listed on line 16 above. None

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed

- 15. General issue area code: PHA (one per page)
- 16. Specific lobbying issues:

H. R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics H. R. 2900, Food and Drug Administration Amendments Act of 2007, PDUFA, drug safety provisions H. R. 3580, Food and Drug Administration Amendments Act of 2007 S. 1024, Safer DATA Act, clinical trials/drug safety provisions S. 1082, Prescription Drug User Fee Amendments of 2007, PDUFA, drug safety provisions S. 1156, Best Pharmaceuticals for Children Amendments of 2007, pediatric exclusivity provisions in FDARA/PDUFA bill S. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 242, Pharmaceutical Market Access and Drug Safety Act of 2007, drug importation provisions S. 4, Improving America's Security Act of 2007, cargo-screening provision S. 467, FACT Act, clinical trials/drug safety provisions S. 484, Enhancing Drug Safety and Innovation Act of 2007, clinical trials/drug safety provisions S. 593, Access to Life-Saving Medicine Act, follow-on biologics S. 993, Pediatric Research Improvement Act, clinical trials/drug safety provisions H. R. 1, Implementing the 9/11 Commission Recommendations Act of 2007, cargo-screening provision H. R. 1038, Access to Life-Saving Medicine Act, follow-on biologics H. R. 1561, Enhancing Drug Safety and Innovation Act of 2007, PDUFA, drug safety provisions

17. House(s) of Congress and Federal agencies contacted: Food & Drug Administration (FDA) HOUSE OF REPRESENTATIVES Health & Human Services, Dept of (HHS) SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BRATHWAITE, PAUL
Covered Official Position (if applicable): EXEC. DIR., CONGRESSIONAL BLACK CAUCUS
Name: COHEN, SHARON
Covered Official Position (if applicable): N/A
Name: PODESTA, ANTHONY
Covered Official Position (if applicable): N/A
Name: POLAK, ANN MARIE
Covered Official Position (if applicable): LEG. CORRESPONDENT FOR REP. MIKE FERGUSON

19. Interest of each foreign entity in the specific issues listed on line 16 above. None

Signature: ON FILE Date: Feb 14, 2008

Printed Name and Title: KIMBERLEY FRITTS, CEO $\,\cdot\,$

Information Update Page:

Complete ONLY where registration information has changed.

LOBBYIST UPDATE

23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that NO LONGER pertain

AFFILIATED ORGANIZATIONS

25. Add the following organization(s)

26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization

Signature: ON FILE Date: Feb 14, 2008

Printed Name and Title: -

Page 6